December 16, 2024
Although the US Food and Drug Administration (FDA) has approved two microbial therapies to prevent recurrent Clostridioides difficile infection (CDI), the preferred treatment of conventional fecal microbiota […]
December 13, 2024
The European Medicines Agency (EMA) has recommended granting marketing authorization for Seladelpar Gilead (seladelpar lysine dihydrate) to treat primary biliary cholangitis (PBC). PBC is a chronic […]
December 6, 2024
TOPLINE: Patients with inflammatory bowel disease (IBD) face a higher risk for complications of herpes zoster than those without IBD, with older age, higher comorbidity scores, […]
December 6, 2024
TOPLINE: The use of glucagon-like peptide 1 (GLP-1) receptor agonists is associated with a reduced risk for poor inflammatory bowel disease (IBD)–related outcomes in patients with […]
December 5, 2024
TOPLINE: The use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for obesity treatment increased more than twofold between the last half of 2022 and the […]
December 5, 2024
TOPLINE: A 12-month period of histological inflammation is linked to a modestly increased risk for fracture in patients with inflammatory bowel disease (IBD), with the most […]
December 5, 2024
Between 20% and 30% of hospitalized patients in Germany suffer from malnutrition, which may result in serious consequences in some cases. “Malnutrition is not a minor […]
November 28, 2024
SAN DIEGO — In patients with severe alcohol-associated hepatitis (SAH), tapering corticosteroids appears to be safer and as effective as a conventional fixed dose, according to […]
November 27, 2024
TOPLINE: For initial treatment of eosinophilic esophagitis (EoE), an elimination diet is the most cost-effective option from a payer perspective and proton pump inhibitor (PPI) therapy […]